Agressive Lymphomas

This book summarizes current knowledge of the biology and molecular pathogenesis of aggressive lymphomas and reviews the state of the art in diagnostic and therapeutic strategies. The aim is both to provide the reader with a sound understanding of the very significant progress that has been achieved in the understanding and management of these malignancies over recent years and to facilitate appropriate choice of the therapeutic strategy in individual cases. The assessment of different prognostic parameters are clearly presented in order to permits effective risk stratification that impacts on treatment choice. Recent insights into lymphomagenesis are exemplified and may assist in identifying emerging therapeutic targets. The comprehensive and up-to-date nature of the book will make it an ideal reference for all physicians and researchers interested in lymphoma, including clinicians from various medical specialties, biologists, pathologists, radiologists and nuclear medicine specialist, as well as students.

Professor Georg Lenz is Director of the Department of Medicine A, Hematology, Oncology and Pneumology at the University Hospital in Munster, Germany. Before his move to Munster he previously worked at the Ludwig-Maximilians University Munich, the National Cancer Institute in Bethesda (USA), and the Charite - Universitatsmedizin Berlin. His basic and clinical research focuses on the molecular characterization of malignant lymphomas and the performance of clinical trials using specific therapeutics.

Professor Gilles Salles is Head of the Hematology Department in Lyon University Hospitals (Hospices Civils de Lyon & Universite Claude Bernard Lyon-1) and co-director of the research team “Clinical and Experimental Models of Lymphoma” at the Cancer Research Center of Lyon (Institut National de la Sante et de la Recherche Medicale). He trained in Hematology and Immunology at the Universite Claude Bernard in Lyon and at the Dana Farber Cancer Institue (Havard Medical Scholl, Boston, USA). He conducted several leading international clinical trials as well as translational studies in the field of lymphoma.